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Edited by Varda RotterAbstract Activation of an over-expressed mutant form of the
tumour suppressor protein p53 has been shown to inhibit protein
synthesis. To determine whether this eﬀect is due only to high
level expression or the mutant nature of the protein, we have used
a doxycycline-inducible lung carcinoma cell line capable of
expressing wild-type p53. We now show that levels of wild-type
p53 similar to those expressed endogenously also inhibit protein
synthesis. The mechanism involves dephosphorylation and accu-
mulation of the translational inhibitor 4E-BP1, and increased
association of 4E-BP1 with initiation factor eIF4E. The inhibition
of translation is not a consequence of p53-mediated apoptosis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The p53 protein is a well characterised tumour suppressor
gene product that is activated by a variety of physiological
stresses, including DNA damage and oncogene activation [1–
4]. Mutations of the p53 gene are common in a wide range
of tumours, indicating the importance of p53 as a means of
protecting cells from uncontrolled proliferation. P53 functions
primarily as a transcription factor, controlling expression of
genes involved in cell proliferation, DNA damage repair and
cell survival [5,6]. Not all of the eﬀects of p53 require de novo
transcription however [7–9].
We have previously shown that a temperature-sensitive mu-
tant form of murine p53 (Val135) rapidly inhibits protein syn-
thesis in murine erythroleukaemia (MEL) cells when it is
activated at the permissive temperature [10–12]. However, it
was not clear whether the inhibition was a consequence of
the high level of expression of p53 in the MEL cell system
and/or whether it was a speciﬁc property of the mutant form
of the protein. To explore these issues we have used a p53-neg-
ative human lung carcinoma cell line (H1299) containing a sta-Abbreviations: 4E-BP1, eukaryotic initiation factor 4E-binding protein
1; eIF, eukaryotic initiation factor; MEL, murine erythroleukaemia;
PARP, poly(ADP-ribose) polymerase
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[13]. In this system p53 is induced rapidly to physiologically
normal levels upon addition of doxycycline, allowing us to
measure the rate of overall protein synthesis as a function of
time after expression of the wild-type gene. Our data indicate
that, like the temperature-sensitive form of p53 previously
studied, wild-type p53 can also inhibit translation. The inhibi-
tion precedes the development of a p53-induced cell cycle
block and occurs in the absence of apoptosis. We show that
eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)
and eIF4E, but not the polypeptide chain initiation factor
eIF2a, are targets for regulation by wild-type p53, suggesting
that p53 regulates translation by limiting the availability of
eIF4E for cap-dependent initiation.2. Materials and methods
2.1. Cell culture and induction of p53
H1299 cells containing a Tet-inducible plasmid expressing wild-type
p53 and H1299 cells expressing an inactive p53 mutant (His175) were
maintained in exponential growth in DMEM medium containing 10%
foetal calf serum. Appropriate concentrations of G418 (400 lg/ml)
and puromycin (1 lg/ml) were added to maintain selection of the stably
transfected cells. Expression of wild-type p53 was induced with 2 lg/ml
doxycycline for the times indicated. Cell numbers were determined in a
haemocytometer and cell viability was determined using theMTT assay
(Roche) according to the manufacturer’s instructions. Cell cycle analy-
sis was performed by ﬂuorescence-activated cell sorting of cells stained
with propidium iodide, as described previously [11]. MEL cells and
MCF-7 breast cancer cells were grown and theMCF-7 cells treated with
etoposide (100 lg/ml) as previously described [12,14].
2.2. Antibodies
Antibodies against the following proteins were as described previ-
ously [14], or were obtained from the sources indicated: p53 and phos-
phorylated eIF2a (Ser51) – Biosource; p21 – Becton Dickinson; PARP
– Trevigen; total eIF2a – [14]; total 4E-BP1 and phosphorylated 4E-
BP1 (Ser65) – cell signaling technology. Anti-eIF4E was a gift from
Dr. Simon Morley (University of Sussex).
2.3. Measurement of rates of protein synthesis
Total protein synthesis was measured by pulse-labelling the cells in
low methionine medium (DMEM minus methionine containing 5%
(v/v) undialysed serum) with [35S]methionine (10 lCi/ml) for 60 min.
The radioactivity incorporated into trichloroacetic acid-insoluble
material was determined by liquid scintillation counting [14].
2.4. Immunoblotting
Cell extracts were prepared by lysing cells in a buﬀer containing
20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA and 1% (v/v) Triton-X100, with protease inhibitors (Rocheblished by Elsevier B.V. All rights reserved.
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phate, 1 mM Na vanadate and 1 mM b-glycerophosphate). For frac-
tionation into nuclei and cytoplasm, extracts were centrifuged at
10,000 · g for 10 min at 4 C. Preparations were subjected to SDS
gel electrophoresis as previously described [14]. Proteins were trans-
ferred to PVDF paper and analysed for levels and phosphorylation
states of speciﬁc polypeptide chain initiation factors by immunoblot-
ting and enhanced chemiluminescence detection [12,14].
2.5. m7GTP-sepharose aﬃnity chromatography
Polypeptide chain initiation factor eIF4E and associated proteins
were isolated by aﬃnity chromatography of cell extracts (400 lg pro-
tein) on m7GTP-sepharose (50 ll) [14]. Material puriﬁed from equal
amounts of cell protein was then analysed by gel electrophoresis and
immunoblotting as indicated above.3. Results
3.1. Eﬀects of p53 induction on cell growth and survival
When H1299 cells with the inducible vector for wild-type p53
were treated with doxycycline the tumour suppressor protein
was maximally induced within 24 h (Fig. 1A). The protein accu-
mulated in both nucleus and cytoplasm (Fig. 1A and C). More-
over this p53 was transcriptionally active, as judged by the de
novo appearance of the cyclin-dependent kinase inhibitor p21,
a well characterised product of p53-regulated gene expression
[15] (Fig. 1B). We have compared the level of expression of
p53 in this cell systemwith that seen in the temperature-sensitive
MEL cells previously used by us to study translational control
by p53 [10–12]. As shown in Fig. 1C, the level of wild-typeFig. 1. Induction of transcriptionally active p53 by doxycycline and compari
cells, stably transfected with a Tet-inducible wild-type p53 gene, were incubate
cytoplasmic (B) fractions were prepared and blotted for p53 and p21 respec
induced H1299 cells as in (A). Extracts were also prepared from MEL cells
that had been incubated at 32 C for 16 h (left panel) and from control and
three cell types were analysed for p53 and p21 levels by immunoblotting. N
exposures were used for the blots in the left panels compared to the right pap53 in the induced H1299 cells was far lower than in the MEL
cells constitutively expressing the Val135 mutant form of p53.
However, it was comparable with the level of endogenous
wild-type p53 that was present after treatment of a human cell
line (MCF-7) with the DNA-damaging agent etoposide
(Fig. 1C). Similarly, p21 was expressed at comparable levels
in both the induced H1299 cells and the etoposide-treated
MCF-7 cells. Interestingly, although the MEL cells contain
much higher levels of p53, after activation of the latter at
32 C for 16 h these cells only expressed p21 to an extent similar
to that seen in the induced H1299 cells (Fig. 1C). This may be a
consequence of a relatively low level of p21 gene transcription
and/or a high rate of p21 protein turnover in MEL cells. A sim-
ilar lack of correlation between p53 and p21 expression has been
reported in other systems [16].
Fig. 2A shows that p53 induction progressively inhibited
H1299 cell proliferation, with a particularly marked eﬀect after
3 days. However, cell viability remained high throughout, as
measured by the MTT assay (Fig. 2B). This suggests that, in
this system, p53 induces a cell cycle block rather than apopto-
sis. To conﬁrm this, cell cycle analysis was carried out by ﬂuo-
rescence-activated cell sorting of cells stained for DNA content
with propidium iodide. Fig. 2C shows that even after 4 days of
doxycycline treatment less than 5% of the cells had a sub-G1
DNA content. Rather, the cells were blocked in both G1 and
G2 phases of the cell cycle as previously observed in studies
using similar inducible p53 cell systems [17,18]. As another
measure of apoptosis we performed immunoblotting analysis
of the integrity of the well characterized caspase substrateson with p53 levels in other cell types. (A) and (B) P53-negative H1299
d with or without doxycycline for the times indicated. Nuclear (A) and
tively. (C) Cytoplasmic extracts were prepared from control and 72 h-
constitutively expressing the temperature-sensitive p53 mutant, Val135,
24 h etoposide-treated MCF-7 cells (right panel). The extracts from all
ote that, because of the high level of p53 in MEL cells, much shorter
nels.
Fig. 2. Induction of p53 inhibits cell growth but does not lead to apoptosis in H1299 cells. (A) Cells containing the Tet-inducible wild-type p53 gene
were incubated with or without doxycycline for the times indicated and counted in a haemocytometer at daily intervals. After 3 days the cells were
diluted to maintain sub-conﬂuence. The data are calculated from the cell numbers, as % of the control values, allowing for this dilution factor. (B)
Cells were treated as in (A), harvested and re-seeded at identical densities. The cell viabilities were determined 3 h later using the MTT assay. The
data are the means of ﬁve determinations. (C) Cells were treated as in (A) and harvested at 0–4 days for analysis of DNA content by ﬂuorescence-
activated cell sorting. Data are shown for control cells and cells induced to express p53 for 2 or 4 days. In each panel the % of cells with a DNA
content corresponding to sub-G1 (apoptotic) cells and cells in the G1, S and G2 phases of the cell cycle (fractions M1–M4, respectively) are shown.
Similar results were obtained at 1 day and 3 days of doxycycline treatment (not shown). (D) Cells were treated as in (A) and extracts prepared and
blotted for poly(ADP-ribose) polymerase (PARP).
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only the full-length form of PARP (116 kDa) was detected
and there was a complete absence of the 85 kDa caspase cleav-
age product, even after 3 days of p53 induction. Thus,
although p53 is induced and becomes maximally active within
24 h, in H1299 cells it does not lead to caspase activation.
3.2. Regulation of protein synthesis by wild-type p53
The H1299 cells were pulse-labelled with [35S]methionine at
diﬀerent times after addition of doxycycline. Fig. 3 shows that
total protein synthesis was signiﬁcantly inhibited as a result of
the induction of wild-type p53 within 24 h and the magnitude
of the inhibition increased with time. As a control for any non-
speciﬁc eﬀects of doxycycline, the compound was added to an-
other line of H1299 cells expressing an inactive mutant of p53
(His175). In these cells doxycycline had no eﬀect on protein syn-
thesis, even after 72 h (inset to Fig. 3). These data conﬁrm our
previous conclusions from the MEL cell system that p53
down-regulates protein synthesis [10] and indicate that such
translational inhibition can occur in response to physiological
levels of the wild-type form of the protein. The inhibition of
translation is not a consequence of apoptosis since we ﬁnd
no evidence for activation of cell death over the ﬁrst three days
of induction of p53 in the H1299 cells.To explore the molecular mechanisms underlying the inhibi-
tion we have examined the levels and state of phosphorylation
of key initiation factors that are regulated by cellular stress con-
ditions, viz. eIF2 and eIF4E and the inhibitory eIF4E binding
protein 4E-BP1 [19]. Fig. 4 shows that there was a signiﬁcant
level of phosphorylation of the a subunit of eIF2 at position
Ser51 in the control cells but no increase in the level of this
inhibitory phosphorylation following p53 induction (indeed a
slight decrease was evident). The absence of any p53-induced
increase in Ser51 phosphorylation conﬁrms our observations
in MEL cells with temperature-sensitive p53 and suggests that
p53 does not activate PKR or any of the other eIF2a kinases
(PERK, HRI and GCN2) that phosphorylate this site [20].
We have also failed to see any changes in the level or state of
phosphorylation of initiation factor eIF2B (data not shown).
Thus we conclude that the p53-mediated inhibition of protein
synthesis is unlikely to be due to decreased eIF2 or eIF2B activ-
ity caused by eIF2a phosphorylation.
There was no change in the level of eIF4E following p53
induction (data not shown), indicating that the eﬀects of p53
are not due to a decrease in the abundance of this factor. In
contrast, there was an increase in the total amount of 4E-
BP1 and a marked change in the proportions of the diﬀeren-
tially phosphorylated forms of this protein. This was evident
Fig. 3. Induction of p53 results in progressive inhibition of protein
synthesis. Cells containing the Tet-inducible wild-type p53 gene were
incubated with or without doxycycline for the times indicated. Rates of
overall protein synthesis were determined by [35S]methionine incorpo-
ration into acid-insoluble material (1 h pulse label) and are expressed
as counts per min per lg protein. The data are the means ± SEM. of
three determinations. Inset: As a control a similar experiment was
performed using cells expressing an inactive p53 mutant (His175),
treated with or without doxycycline for 72 h.
Fig. 4. p53-induced inhibition of protein synthesis is not associated
with increased phosphorylation of eIF2a. Cells containing the Tet-
inducible wild-type p53 gene were incubated with or without doxycy-
cline for the times indicated. Cell extracts were prepared and blotted
for (A) total eIF2a and (B) eIF2a phosphorylated on Ser51.
Fig. 5. p53-induced changes in the level and state of phosphorylation
of 4E-BP1 and in the association of 4E-BP1 with eIF4E. Cells
containing the Tet-inducible wild-type p53 gene were incubated with or
without doxycycline for the times indicated. Cell extracts were
prepared and blotted for (A) total 4E-BP1 and (B) 4E-BP1 phosphor-
ylated on Ser65. (C) Initiation factor eIF4E and its associated proteins
were isolated by m7GTP-sepharose chromatography, subjected to SDS
gel electrophoresis and blotted for eIF4E and 4E-BP1 as indicated.
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phorylated form (upper band) towards less phosphorylated
forms (Fig. 5A) and from a strong reduction in the extent of
phosphorylation of 4E-BP1 on Ser65 (Fig. 5B). Dephosphoryl-
ation of 4E-BP1 is associated with increased sequestration of
eIF4E by this protein [21,22]. To examine whether this was
the case with p53 induction we puriﬁed eIF4E and its associ-
ated proteins by aﬃnity chromatography on m7GTP-sephar-
ose and analysed the level of 4E-BP1 in this fraction by
immunoblotting. Fig. 5C shows that there was a large increase
in the binding of hypophosphorylated 4E-BP1 to eIF4E fol-
lowing p53 induction, evident at 24 and 48 h. At the 48 and
72 h time-points there was also some binding of 4E-BP1 to
eIF4E in the control cells, perhaps related to increased density
of the exponentially growing cell population at these times.The dephosphorylation and accumulation of 4E-BP1, and
the increased association of 4E-BP1 with eIF4E, after induc-
tion of p53 in the H1299 cells provides a mechanistic explana-
tion for the inhibition of protein synthesis by the tumour
suppressor protein, especially at the earlier time-points. It also
indicates that the wild-type form of the protein is capable of
regulating translation at this level when expressed at physio-
logically normal concentrations in the cell.4. Discussion
We have shown that wild-type p53, when inducibly ex-
pressed in cells with a p53-null background, is capable of caus-
ing the dephosphorylation and accumulation of the
translational regulatory factor 4E-BP1. The resulting inhibi-
tion of overall protein synthesis occurs in the absence of any
overt signs of apoptotic cell death, as judged by the lack of
DNA degradation or PARP cleavage. The eﬀects on transla-
tion are observed at a level of expression of the ectopic p53
which is comparable to that of the endogenous p53 that accu-
mulates in cells treated with a DNA-damaging agent. Our
previous data have shown that activation of a temperature-
sensitive mutant form of p53 that is constitutively over-
expressed in MEL cells results in inhibition of protein synthesis
which precedes a p53-induced cell cycle block and the irrevers-
ible commitment of the cells to apoptosis [11]. However, it was
not clear whether the eﬀects on translation were a peculiarity
of the high level of expression of the p53 and/or a speciﬁc
property of the mutant form of the protein studied. On the ba-
sis of the present results neither of these concerns appears to be
justiﬁed.
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increased binding of 4E-BP1 to eIF4E. In the H1299 cells this
may be a consequence both of the dephosphorylation of 4E-
BP1 and a p53-induced increase in the overall level of this
protein. It is possible that these two eﬀects are related, perhaps
because 4E-BP1 becomes stabilized when in its hypophosph-
orylated form. We have also observed both phenomena to
occur when MCF-7 cells are treated with the pro-apoptotic
cytokine TRAIL (I.W. Jeﬀrey, V.J. Tilleray and M.J. Clemens,
unpublished data). However, further studies are required to
determine the inﬂuence of phosphorylation on the turnover
of 4E-BP1.
We have not seen any evidence for the involvement of eIF2a
phosphorylation in the response of protein synthesis to p53, in
either the H1299 or MEL cells. In the latter we also saw partial
cleavages of both 4E-BP1 and initiation factor eIF4GI follow-
ing p53 activation. These were caspase-independent events and
were not a consequence of p53-mediated apoptosis [11,12].
However, neither of these changes has been observed in the
doxycycline-inducible H1299 cell system (Fig. 5 and data not
shown), suggesting that inhibition of translation by p53 is at
least partially independent of initiation factor cleavages. It is
possible that such events do contribute to translational
down-regulation but only when there are high levels of expres-
sion or activity of p53. It should also be noted that, in the pres-
ent studies, we have not exposed the doxycycline-treated cells
to any DNA damaging agent or other stress. Thus, although
p21 was induced, the ectopically expressed p53 may not have
been fully activated by the post-translational modiﬁcations
that are enhanced by such stimuli. Nevertheless, it is clear that
protein synthesis can be down-regulated by p53 in the absence
of DNA damage or other stresses.
In conclusion, our data suggest that inhibition of protein
synthesis via regulation of the 4E-BP1/eIF4E system consti-
tutes a physiologically relevant facet of the inhibition of cell
proliferation by p53, which can be separated from any inﬂu-
ence of the tumour suppressor protein on apoptosis. Identiﬁca-
tion of the signal transduction pathways involved in bringing
about the eﬀects of p53 on the translational machinery requires
further investigation. In particular, it remains to be established
whether the mechanism depends on prior transcriptional
changes mediated by p53 or whether, as in the case of the reg-
ulation of mitochondrial function by the protein [7–9], p53 has
a more direct eﬀect.
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